{"id":"blex-404-oral-liquid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, BLEX 404 Oral Liquid reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of how BLEX 404 Oral Liquid interacts with the SGLT2 receptor are not well understood.","oneSentence":"BLEX 404 Oral Liquid is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:38.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05764928","phase":"PHASE1, PHASE2","title":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","status":"NOT_YET_RECRUITING","sponsor":"Rgene Corporation","startDate":"2026-01-01","conditions":"Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":32},{"nctId":"NCT02802423","phase":"PHASE1, PHASE2","title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"BioLite, Inc.","startDate":"2026-01-01","conditions":"Triple Negative Breast Cancer","enrollment":44},{"nctId":"NCT02944955","phase":"PHASE2","title":"A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)","status":"NOT_YET_RECRUITING","sponsor":"BioLite, Inc.","startDate":"2026-01-01","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":52},{"nctId":"NCT03301805","phase":"PHASE2","title":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rgene Corporation","startDate":"2025-07-01","conditions":"Pancreatic Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BLEX 404 Oral Liquid","genericName":"BLEX 404 Oral Liquid","companyName":"BioLite, Inc.","companyId":"biolite-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BLEX 404 Oral Liquid is being studied in clinical trials for the treatment of pancreatic cancer, nonsquamous nonsmall cell neoplasm of lung, triple negative breast cancer, and myelodysplastic syndrome (MDS). The exact mechanism of BLEX 404 Oral Liquid is unknown, but it is being evaluated in combination with gemcitabine monotherapy in a Phase II study for pancreatic cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}